Update on the use of analgesics versus nonsteroidal anti-inflammatory drugs in rheumatic disorders: Risks and benefits

Current Opinion in Rheumatology

Volumn 20, Issue 3, 2008, Pages 239-245

  McKellar, Gayle ^a   Madhok, Rajan ^a   Singh, Gurkirpal ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arthritis; Nonsteroidal anti inflammatory drugs; Opioids; Pain; Paracetamol

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ADALIMUMAB; AMITRIPTYLINE; ANALGESIC AGENT; CELECOXIB; CODEINE; CYCLOOXYGENASE 2 INHIBITOR; DEXTROPROPOXYPHENE; DICLOFENAC; ESOMEPRAZOLE; ETANERCEPT; FENTANYL; HYDROMORPHONE; IBUPROFEN; INFLIXIMAB; METHOTREXATE; MORPHINE; MORPHINE SULFATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OPIATE; OXYCODONE; PARACETAMOL; ROFECOXIB; SALAZOSULFAPYRIDINE; TRAMADOL;

ACUPUNCTURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALGESIA; ANKYLOSING SPONDYLITIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; KNEE PAIN; LIVER FUNCTION; LIVER TOXICITY; LOW BACK PAIN; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; SURGICAL TECHNIQUE; TRANSCUTANEOUS NERVE STIMULATION; VOMITING;

ANALGESICS; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; HUMANS; PAIN; RHEUMATIC DISEASES; RISK ASSESSMENT;

EID: 41649113735     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282fb03ec     Document Type: Review

References (47)

1. Minnock P, FitzGerald O, Bresnihan B. Women with established rheumatoid arthritis perceive pain as the predominant impairment of health status. Rheumatology 2003; 42:995-1000.
2. Ødegård S, Finset A, Mowinckel P, et al. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2007; 66:1195-1201.
3. American College of Rheumatology Subcommittee on osteoarthritis guidelines. Recommendations for medical management of hip and knee osteoarthritis: 2000 update. Arthritis Rheum 2000; 43:1905-1915.
4. Lee Y-S, Hyungsuk K, Brahim JS, et al. Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain 2007; 129:279-286. Although the results of this study come from an oral surgery background (extraction of impacted third molars), we can still extrapolate helpful information from their scientific work when paracetamol was compared with rofecoxib and ketorolac in terms of thromboxane2 and prostaglandin E2 release.
5. Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooygenase-2 inhibitor in man. FASEB J; doi: 10.1096/fj.07-8506com. Accessed 31 December 2007.
6. Altman RD, Zinsenheim JR, Temple AR, Schweine JE. Three-month efficacy and safety of acetaminophen extended-release for osteoarthritis pain of the hip or knee: a randomised, double-blind, placebo-controlled study. Osteoarthritis Cartilage 2007; 15:454-461. A study showing the potential benefit of extended release paracetamol preparation in patients with osteoarthritis over a 12-week period.
7. Yaghi C, Honein K, Boujaoude J, et al. Influence of acetaminophen at therapeutic doses on surrogate markers of severity of acute viral hepatitis. Gastroenterol Clin Biol 2006; 30:763-768.
8. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. JAMA 2006; 296:87-93.
9. Jalan R, Williams R, Bernuau J. Paracetamol: are therapeutic doses entirely safe? [comment]. Lancet 2006; 368:2195-2196.
10. Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004; 164:1519-1524.
11. González-Pérez A, García Rodríguez LA. Upper gastrointestinal complications among users of paracetamol. Basic Clin Pharmacol Toxicol 2006; 98:297-303.
12. Forman JP, Stampfer MJ, Curhan GC. Nonnarcotic analgesic use and risk of incident hypertension in US women. Hypertension 2005; 46:500-507.
13. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007; 167:394-399. Further detailed work from the team who have previously analysed the Nurses Health Study from a similar perspective. This study reports that frequent non-narcotic analgesic use is independently associated with a modest increase in risk of incident hypertension.
14. Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with nonselective nonsteroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006; 8:R153.
15. Hernandez-Diaz S, Varas-Lorenzo C, García Rodríguez LA, et al. Nonsteroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98:266-274.
16. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2-inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? BMJ 2006; 332:1302-1308.
17. McGettigan P, Henry D. Cardiovascular risk of inhibition of cyclo-oxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclo-oxygenase-2. JAMA 2006; 296:1633-1644.
18. Lapeyre-Mestre M, Rueda de Castro AM, Bareille M-P, et al. Nonsteroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 2006; 20:391-395.
19. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364:665-674.
20. Farkouh ME, Kirschner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004; 364:675-684.
21. Medicines and Healthcare products Regulatory Authority. Lumiracoxib (Prexige): suspension of marketing authorisation; 2007. www.mhra.gov.uk/home/ idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName= -CON2033073&ssTargetNodeId=221. Accessed 25 January 2008.
22. Lanas A, García Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin and combinations. Gut 2006; 55:1731-1738.
23. Chan FKL, Wong VWS, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369:1621-1626. Further detailed analysis from a world-renowned unit on the subject of COX2s combined with proton pump inhibitor. Despite a lack on nonselective NSAID comparator, this study does add helpful information on the potential benefits of their coprescription.
24. Ong CKS, Lirk P, Tan CH, Seymour RA. An evidence based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007; 5:19-34. A comprehensive review of NSAID efficacy and their adverse effects. The paper concludes with a helpful algorithm to aid decision making in the use of analgesics in different clinical contexts.
25. Catella-Lawson F, Reilly M, Kapoor SC. Cylcooxygenase inhibitors and the antiplatelet effects of aspirin. N Eng J Med 2001; 345:1809-1817.
26. United States Food and Drug Agency. Information for healthcare professionals: concomitant use of ibuprofen and aspirin. Issued September 2006. http://www.fda.gov/cder/drug/InfoSheets/HCP/ibuprofen_aspirinHCP.htm. Accessed 31 December 2007.
27. Singh G, Graham D, Wang H, et al. Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cyclo-oxygenase-2-selective and some nonselective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65:S61.
28. Goldstein JL, Cryer B, Amer F, Hunt B. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol 2007; 5:1167-1174. A large endoscopic trial of 1045 patients with osteoarthritis. This showed that irrespective of prescribed aspirin dose, no difference in the occurrence of gastroduodenal ulcers was seen between NSAID and COX2 groups.
29. Strand V. Are COX-2 inhibitors preferable to nonselective nonsteroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370:2138-2151. This is an in-depth and detailed review of the latest evidence and controversies surrounding COX2 and NSAID prescription, with regards to cardiovascular and gastrointestinal risks. An area of recent debate has been around the co-administration of aspirin and antiinflammatories and this is covered in detail with prescribing recommendations given.
30. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006; 174:1589-1594.
31. Solomon DG, Avorn J, Wang PS, et al. Prescription opioid use among older adults with arthritis or low back pain. Arthritis Rheum 2006; 55:35-41.
32. Oxford League Table of Analgesics in Acute Pain. Bandolier website http://www.jr2.ox.ac.uk/bandolier/booth/painpag/Acutrev/Analgesics/Leagtab.html. Accessed 31 December 2007.
33. Capeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database of Systematic Reviews 2006; 3. Article No. CD005522. doi: 10.1002/14651858.CD005522.pub2.
34. Lee EY, Lee EB, Park BJ, et al. Tramadol 37.5 mg/acetaminophen 325 mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1 week randomised, double-blind, placebo-controlled trial. Clin Ther 2006; 28:2052-2060.
35. Choi C-B, Song JS, Kang YM, et al. A 2-week, multicenter, randomised, double-blind, double-dummy, add-on study of the effects of titration on tolerability of tramadol/acetaminophen combination in Korean adults with knee osteoarthritis pain. Clin Ther 2007; 29:1381-1389. In this, albeit short, study, up-titration of combination paracetamol/tramadol tablets was associated with lower side effects and subsequent lower discontinuation rates.
36. Langford R, McKenna F, Ratcliffe S, et al. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum 2006; 54:1829-1837.
37. Berliner MN, Giesecke T, Bornhölvd KD. Impact of transdermal fentanyl on quality of life in rheumatoid arthritis. Clin J Pain 2007; 23:530-534. One of the few recent studies evaluating the use of tramadol specifically in patients rheumatoid arthritis.
38. Martell BA, O'Connor PG, Kerns RD, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy and association with addiction. Ann Intern Med 2007; 146:116-127. This is an extremely thorough study detailing the use of opioids in the treatment of low back pain. The links with dependence are discussed.
39. Deshpande A, Furlan A, Mallis-Gagnon A, et al. Opioids for chronic low-back pain. Cochrane Database of Systematic Reviews 2007; 3. Article No. CD004959. doi: 10.1002/14651858.CD004959.pub3. A detailed analysis of the current evidence surrounding the use of opioids in chronic low-back pain. The authors conclude that further detailed studies are required to specifically evaluate the risks and benefits of such therapies in clinical practice.
40. Chou R, Huffman LH. Medications for acute and chronic low back pain: a review of the evidence for an American Pain society/American College of Physicians Clinical Practice Guideline. Ann Intern Med 2007; 147:505-514. A detailed study analysing the evidence for different therapies in the treatment of both acute and chronic back pain, with information taken from systematic reviews and randomized trials. The authors conclude that one medication alone cannot be recommended because of the individualized nature of risk versus benefit in each patient.
41. Capell HA, Madhok R, Porter DR, et al. Combination therapy with sulfasalzine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalzine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007; 66:235-241. A useful study demonstrating the benefits of combination DMARD therapy with regards to hard-outcomes, such as disease activity and radiological changes, as well as patient reported symptoms of pain.
42. Verstappen SMM, Jacobs JWG, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66:1443-1449.
43. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005; CD005113.
44. Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. Rheumatology 2005; 32:1232-1242.
45. Lipsky PE, van der Heijde DMFM, St. Clair W, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594-1602.
46. Wienblatt M, Combe B, Covucci A, et al. Safety of the selective co-stimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54:2807-2816.
47. Ten Klooster PM, Veehof M, Taal E, et al. Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of antitumour necrosis factor treatment. Ann Rheum Dis 2007; 66:1485-1490. This is a practical analysis of the impact of anti-tumour necrosis factor therapy on patient's pain control in RA. Importantly, it highlights that although pain may be better controlled with biologic therapy, it remains a very important concern for patients.